Skip to main content

Table 1 Results from univariate logistic regression with HRD scores or clinical variables as predictors of BRCA1/2 deficiency

From: Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

  Number of patients Number BRCA1 / 2 deficient P value OR (95% CI)
HRD-LOH score 197 38 1.3 × 10-17 22 (8.4, 58)
HRD-TAI score 197 38 1.5 × 10-19 17 (7.2, 41)
HRD-LST score 197 38 3.5 × 10-18 19 (7.7, 46)
HRD-mean score 197 38 1.1 × 10-24 90 (22, 360)
Age at diagnosis 196 37 0.0071 0.96 (0.94, 0.99)
Stage    0.88  
  I 13 3   1
  II 121 23   0.78 (0.2, 3.1)
  III 54 9   0.67 (0.15, 2.9)
  IV 3 1   1.7 (0.11, 25)
Cancer subtype    1.2 × 10-5  
  TNBC 52 23   8.5 (2.3, 31)
  ER /HER2 + 35 3   1
  ER +/HER2 50 5   1.2 (0.26, 5.3)
  ER +/HER2 + 60 7   1.4 (0.34, 5.8)
Gradea (categorical)    0.0011 NA
  1 17 0   1
  2 102 14   ∞ (0, ∞)
  3 71 21   ∞ (0, ∞)
Grade (numerical)    0.00053 3.1 (1.6, 6.3)
  1. Odds ratios for HRD scores are reported per interquartile range of the score. The odds ratio for age is reported per year. The odds ratio for grade (numerical) is per unit. CI, confidence interval; ER, estrogen receptor; HER2, tyrosine kinase-type cell surface receptor HER2; HRD, homologous recombination deficiency; HRD-LOH, homologous recombination deficiency-loss of heterozygosity; HRD-LST, homologous recombination deficiency-large-scale state transition; HRD-Mean, mean of the three HRD scores; HRD-TAI, homologous recombination deficiency-telomeric allelic imbalance; NA, not available; OR, odds ratio; TNBC, triple-negative breast cancer. aThe odds ratio for categorical grade is inestimable due to zero BRCA1/2-deficient grade 1 tumors.